Seminar Series

IDP Conversations

Date and Time

07 July 2021
11AM (EDT) / 5PM (CEST)

Session Link

The seminar series will be recorded and may be shared for later viewing.

Past Sessions

New Equilibrium presents IDP Conversations, a monthly seminar series focused on intrinsically disordered proteins (IDPs). Our goal is to foster a multi-perspective discussion on modeling and targeting IDPs. Each seminar, featuring speakers across academia and industry, includes a 40-minute presentation followed by a conversation.

From a Design on a Napkin to a Clinical Trial: a 20-year quest to improve survival for Ewing sarcoma patients

In 2009, Dr. Toretsky and his team revealed the molecule called YK-4-279 that targets Ewing sarcoma with an article in Nature Medicine. A deeper investigation into the mechanism of YK-4-279 has led Dr. Toretsky into the world of phase separation and soft matter. An analog of YK-4-279 called TK216 is in human clinical trials and seems to be helping some patients. This is the story that will be told.

Speaker: Jeffrey Toretsky

Dr. Jeffrey Toretsky received his MD in 1988 from the University of Minnesota. He completed his pediatric residency at the Medical College of Virginia in 1991, and his pediatric oncology fellowship at the National Cancer Institute Pediatric Branch in 1997. In 2002, Dr. Toretsky was recruited from the University of Maryland to Georgetown University; where he was promoted to full professor with tenure in 2011. He was inducted into the American Society of Clinical Investigation in 2007 and received the Burroughs-Wellcome Clinical Scientist Award in Translational Research in 2008. In 2018, Toretsky was inducted into the National Academy of Inventors.
 
Dr. Toretsky actively pursues research that will lead to new and more specific therapies for a very rare cancer, Ewing sarcoma. His work focuses on Ewing sarcoma, since the tumors contain a unique target that is not found in non-tumor cells. This unique target offers an opportunity to create new medicines that will more specifically eliminate tumor growth while sparing normal cells. In 2009, Dr. Toretsky and his team revealed the molecule called YK-4-279 that targets Ewing sarcoma with an article in Nature Medicine. YK-4-279 has the potential to be a potent new strategy in the fight against not only Ewing sarcoma, but also other cancers and diseases with similar characteristics. A deeper investigation into the mechanism of YK-4-279 has led Dr. Toretsky into the world of phase separation and soft matter. He is particularly interested in understanding how protein complexes he called ‘assemblages’ occur and how they function in RNA processing. Along with this, he cofounded Tokalas, Inc., now Oncternal, Inc., to advance YK-4-279 to a clinical trial that began in the spring of 2016. 
 
Dr. Toretsky is now Chief of the Division of Pediatric Adolescent and Young Adult Hematology/Oncology at Georgetown University. He continues to be the principal investigator of his NIH-funded laboratory group, leads the Molecular Oncology Program of the Lombardi Comprehensive Cancer Center, and co-leads a multidisciplinary sarcoma clinic at Children’s National Medical Center. He continues to be engaged in teaching at levels from high school through faculty mentoring. His wife, three children, dogs (Lucy and Greta), a passion for SCUBA diving and a clarinet support him in these endeavors.

Seminar Registration

Your contact information will not be shared with any third parties and will only be used for seminar registration/announcements. If you are interested in hearing from a particular speaker, please let us know via idpconversations@newequilibriumbio.com.
* indicates required